According to the latest report published by the Spanish Agency for Medicines and Health Products (AEMPS) in its annual Veterinary Pharmacovigilance Bulletin, veterinary medicines showed a higher level of efficacy, safety and quality on 2020 compared to the previous period.
Every year, the AEMPS publishes all the activities carried out in the field of pharmacovigilance to prove whether the veterinary drugs in force are safe and effective for the animals. The objective is to verify that the Benefit / Risk (B / R) balance of the veterinary drugs maintains the margins that were exposed when their commercialization was approved. Thus, identifying new risks (or significant variations of whether the severity and / or frequency of those previously) is how we can face the associated dangers for public health, animal health and the environment.
Still, we should highlight the direct impact on the products safety the following aspects: human handling of the drug, biosecurity concepts, animals that are in contact, …
The AEMPS emphasize that not because a veterinarian drug is between the allowed margins, it can be qualified as “extraordinary”: never a product is totally harmless or free from potential adverse effects. And this is exactly the origin of this pharmacovigilance: to test that all product in force is being used according to what it is stablished as “safe”.